149 related articles for article (PubMed ID: 27513518)
61. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway.
Li H; Yang B; Huang J; Xiang T; Yin X; Wan J; Luo F; Zhang L; Li H; Ren G
Toxicol Lett; 2013 Jul; 220(3):219-28. PubMed ID: 23694763
[TBL] [Abstract][Full Text] [Related]
62. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.
Zhang Y; Wang Y; Wei Y; Li M; Yu S; Ye M; Zhang H; Chen S; Liu W; Zhang J
Sci Rep; 2015 Oct; 5():15424. PubMed ID: 26487539
[TBL] [Abstract][Full Text] [Related]
63. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
64. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.
Van Raemdonck K; Berghmans N; Vanheule V; Bugatti A; Proost P; Opdenakker G; Presta M; Van Damme J; Struyf S
Oncotarget; 2014 Nov; 5(21):10916-33. PubMed ID: 25373734
[TBL] [Abstract][Full Text] [Related]
65. The Recombinant Fragment of Human κ-Casein Induces Cell Death by Targeting the Proteins of Mitochondrial Import in Breast Cancer Cells.
Richter M; Wohlfromm F; Kähne T; Bongartz H; Seyrek K; Kit Y; Chinak O; Richter VA; Koval OA; Lavrik IN
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486420
[TBL] [Abstract][Full Text] [Related]
66. Antimetastatic Effect of Liposomal Recombinant Lactaptin.
Kaledin VI; Koval OA; Kuligina EV; Lushnikova EL; Nikolin VP; Popova NA; Pyshnaya IA; Richter VA
Bull Exp Biol Med; 2018 Apr; 164(6):762-765. PubMed ID: 29666965
[TBL] [Abstract][Full Text] [Related]
67. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
68. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
[TBL] [Abstract][Full Text] [Related]
69. Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display.
Bussolati B; Grange C; Tei L; Deregibus MC; Ercolani M; Aime S; Camussi G
J Mol Med (Berl); 2007 Aug; 85(8):897-906. PubMed ID: 17384922
[TBL] [Abstract][Full Text] [Related]
70. Interplay Between Mitophagy and Apoptosis Defines a Cell Fate Upon Co-treatment of Breast Cancer Cells With a Recombinant Fragment of Human κ-Casein and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
Wohlfromm F; Richter M; Otrin L; Seyrek K; Vidaković-Koch T; Kuligina E; Richter V; Koval O; Lavrik IN
Front Cell Dev Biol; 2020; 8():617762. PubMed ID: 33537307
[TBL] [Abstract][Full Text] [Related]
71. Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer.
Yang J; Yin H; Yang J; Wei Y; Fang L; Chai D; Zhang Q; Zheng J
Transl Oncol; 2019 Mar; 12(3):453-461. PubMed ID: 30580153
[TBL] [Abstract][Full Text] [Related]
72. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
Chen R; Braun GB; Luo X; Sugahara KN; Teesalu T; Ruoslahti E
Cancer Res; 2013 Feb; 73(4):1352-61. PubMed ID: 23248118
[TBL] [Abstract][Full Text] [Related]
73. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
Isakova AA; Artykov AA; Plotnikova EA; Trunova GV; Khokhlova VА; Pankratov AA; Shuvalova ML; Mazur DV; Antipova NV; Shakhparonov MI; Dolgikh DA; Kirpichnikov MP; Gasparian ME; Yagolovich AV
Int J Biol Macromol; 2024 Jan; 255():128096. PubMed ID: 37972835
[TBL] [Abstract][Full Text] [Related]
74. iRGD Tumor-Penetrating Peptide-Modified Nano-Delivery System Based on a Marine Sulfated Polysaccharide for Enhanced Anti-Tumor Efficiency Against Breast Cancer.
Chen B; Liu X; Li Y; Shan T; Bai L; Li C; Wang Y
Int J Nanomedicine; 2022; 17():617-633. PubMed ID: 35173433
[TBL] [Abstract][Full Text] [Related]
75. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.
Porkka K; Laakkonen P; Hoffman JA; Bernasconi M; Ruoslahti E
Proc Natl Acad Sci U S A; 2002 May; 99(11):7444-9. PubMed ID: 12032302
[TBL] [Abstract][Full Text] [Related]
76. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.
Passarella RJ; Zhou L; Phillips JG; Wu H; Hallahan DE; Diaz R
Clin Cancer Res; 2009 Oct; 15(20):6421-9. PubMed ID: 19825959
[TBL] [Abstract][Full Text] [Related]
77. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
78. A potential peptide vector that allows targeted delivery of a desired fusion protein into the human breast cancer cell line MDA-MB-231.
Liu WQ; Yang J; Hong M; Gao CE; Dong J
Oncol Lett; 2016 Jun; 11(6):3943-3952. PubMed ID: 27313722
[TBL] [Abstract][Full Text] [Related]
79. Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.
Newton-Northup JR; Dickerson MT; Ma L; Besch-Williford CL; Deutscher SL
Clin Exp Metastasis; 2013 Feb; 30(2):119-32. PubMed ID: 22851004
[TBL] [Abstract][Full Text] [Related]
80. Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment.
De G; Ko JK; Tan T; Zhu H; Li H; Ma J
Oncotarget; 2014 Sep; 5(17):7734-47. PubMed ID: 25245280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
